

ILS Laboratories

8222 Vickers St, Suite 106, San Diego, CA 92111
(619) 329-3999 | ils-lab.com

Tirzepatide - 30mg

Tested for: Helia Bio

PASS

COA #: COA-2026-BBJX16
Lot Number: FS408-002
Accession #: ACC-2026-10793
Labeled Content: 30mg

Analysis Date: 08/08/2026
Appearance: Good
Sample Matrix: Lyophilized
Volume: 3mL
Date Received: 07/17/2026



Scan to verify
authenticity at ils-lab.com
Access Code: 6JUJ85CV

Method: Purity, Identity & Quantitation (HPLC), Sterility (PCR), Endotoxin (USP <85>)

Identity

Tirzepatide

Peptide Purity

99.92%



Fentanyl
Free




Tirzepatide 30mg - FS408-002

Purity, Identity & Quantitation (HPLC)

Analyte	Specification	Result	Unit	Status
Peptide Purity (HPLC)	>= 95.0%	99.92%	%	PASS
Net Peptide Content	Report Only	31.37	mg	N/A
Identity (HPLC-RTM)	Tirzepatide	Confirmed	-	PASS
Fentanyl Screen	Immunoassay, 50 ng/mL cutoff	Not Detected	-	PASS

HPLC Chromatogram



Tirzepatide 30mg - FS408-002 : UV Chromatogram

Sterility Testing (PCR)

Test	Specification	Result	Status
Sterility (PCR)	No Growth	No Growth	PASS

Endotoxin Testing (USP <85>)

Test	Specification	Result	Status
Endotoxin (USP <85>)	Report Result	0.072 EU/mL	Reported

About this result: Endotoxin is reported as a quantitative value. Acceptable limits vary by product type and matrix, so no universal pass/fail threshold applies to RUO products. This result is below commonly referenced endotoxin thresholds.



Dr. Greg Kalyuzhny

Dr. Greg Kalyuzhny
Lab Director
8/8/2026

COA #: COA-2026-BBJX16
Access Code: 6JUJ85CV
Verify: portal.ils-lab.com/verify/C1kSyjfw4dw7Vez
Issued: 8/8/2026

Notes & Methodology

1. Date Tested: 08/08/2026. Methods: Purity, Identity & Quantitation (HPLC).
2. The sample was confirmed to be Tirzepatide by HPLC. Identification by chromatographic retention time comparison with a reference standard.
3. Endotoxin tested per USP <85> kinetic turbidimetric method. Acceptance criteria per client specification.
4. Peptide purity determined by RP-HPLC area normalization at 214 nm. Value represents the percentage of the target peptide relative to all peptide-related peaks. Non-peptide process-related impurities, if detected, are excluded from the calculation.



Dr. Greg Kalyuzhny
Lab Director
8/8/2026

COA #: **COA-2026-BBJX16**
Access Code: **6JUJ85CV**
Verify: portal.ils-lab.com/verify/C1kSyjfw4dw7Vez
Issued: 8/8/2026